William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update.

In her role as a laboratory technologist resource coordinator, Amy Nelson has to be prepared to handle whatever questions, concerns or issues come her way from Mayo Clinic Laboratories' clients. That ability to be ready for anything has served her well as her work has shifted and changed during the COVID-19 pandemic.

Mayo Clinic Laboratories has launched a first-in-the-U.S. autoimmune test of the Kelchlike protein 11 antibody, or KLHL11, which is used to detect autoimmune disease associated with testicular cancer.

Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and insight on disease expression.

For patients with chronic lymphocytic leukemia (CLL) — the most common leukemia in adults — advanced testing can not only provide valuable information about their disease state, but peace of mind in the face of a progressive, incurable illness. Oftentimes, however, complex molecular and genetic tests to identify biomarker cues about disease trajectory and treatment intolerance are not performed, putting patients at risk for unmet expectations and unsatisfactory outcomes.

In this episode, William Morice II, M.D., Ph.D., explains his dual leadership role at Mayo Clinic and discusses how engaging in the business of a reference laboratory informs his work within academic medicine.

This “Continual Improvement” webinar will share how the Department of Laboratory Medicine and Pathology at Mayo Clinic provides root cause analysis (RCA) education to lab staff.

The genetic variability of glioma, and its more advanced relative glioblastoma, has made genetic testing to identify biomarkers associated with prognosis and treatment effectivity an integral component of care plan development. However, the acceleration of brain tumor research and discovery translates into an ever-changing testing environment.

Bobbi Pritt, M.D., discusses how Mayo Clinic Labs’ updated PCR assay for West Nile virus provides increased sensitivity to detect virus RNA in multiple sources, identifies two virus lineages, and confirms diagnosis.

In this month’s “Hot Topic,” Joaquín J. García, M.D., highlights the value of Mayo Clinic’s Pathology Consultation practice and provides guidance for optimizing the consult experience with Mayo Clinic Laboratories.

In this episode of Lab Medicine Rounds, Rondell Graham, M.B.B.S., associate professor of Laboratory Medicine and Pathology at Mayo Clinic, discusses the value and challenges of frozen sections.

Last year, when Brian Netzel was redeployed from Mayo Clinic's Biochemical Genetics Lab to a lab testing for COVID-19, he put his skills to work wherever they were needed — alongside hundreds of other Mayo staff doing the same as they battled the pandemic together.

Kevin Halling, M.D., Ph.D., explains how the MayoComplete Solid Tumor panel uses next-generation sequencing to assess 514 clinically significant, cancer-related genes for genetic alterations that offer insight on treatment effectivity.

Part II of this series shows how a breakthrough discovery about how kidney stones form may open the way for new, unorthodox treatments. The discovery was made possible by joining University of Illinois’ geology and biology forces with Mayo Clinic’s urology and nephrology expertise.

A collaborative study between Mayo Clinic and the University of Illinois debunked the previous consensus about how kidney stones grow.